Codexis, Inc. (NASDAQ:CDXS) Position Increased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its position in Codexis, Inc. (NASDAQ:CDXS) by 109.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 602,288 shares of the biotechnology company’s stock after acquiring an additional 314,424 shares during the period. Assenagon Asset Management S.A. owned about 0.73% of Codexis worth $1,620,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Summit Investment Advisors Inc. boosted its stake in Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 3,783 shares during the period. Wolverine Trading LLC purchased a new stake in shares of Codexis in the fourth quarter valued at $56,000. Fiduciary Trust Co acquired a new stake in shares of Codexis in the fourth quarter worth $65,000. Group One Trading LLC acquired a new stake in shares of Codexis in the fourth quarter worth $73,000. Finally, ProShare Advisors LLC grew its holdings in shares of Codexis by 101.1% during the fourth quarter. ProShare Advisors LLC now owns 26,543 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 13,344 shares in the last quarter. Institutional investors and hedge funds own 78.54% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Codexis to a “sell” rating in a research note on Friday, May 16th.

Codexis Stock Performance

CDXS stock opened at $2.22 on Wednesday. The firm has a 50 day simple moving average of $2.34 and a 200 day simple moving average of $3.47. Codexis, Inc. has a 52 week low of $1.90 and a 52 week high of $6.08. The stock has a market cap of $183.93 million, a P/E ratio of -2.24 and a beta of 2.52. The company has a debt-to-equity ratio of 0.59, a quick ratio of 3.64 and a current ratio of 3.72.

Codexis (NASDAQ:CDXS) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). Codexis had a negative return on equity of 118.47% and a negative net margin of 149.47%. The company had revenue of $7.54 million during the quarter, compared to analysts’ expectations of $10.38 million. Research analysts anticipate that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.